KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Research & Development: 2019-2024

Historic Research & Development for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $314.4 million.

  • Recursion Pharmaceuticals' Research & Development rose 62.28% to $121.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $477.7 million, marking a year-over-year increase of 67.27%. This contributed to the annual value of $314.4 million for FY2024, which is 30.34% up from last year.
  • According to the latest figures from FY2024, Recursion Pharmaceuticals' Research & Development is $314.4 million, which was up 30.34% from $241.2 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Research & Development ranged from a high of $314.4 million in FY2024 and a low of $63.3 million during FY2020.
  • For the 3-year period, Recursion Pharmaceuticals' Research & Development averaged around $237.1 million, with its median value being $241.2 million (2023).
  • Data for Recursion Pharmaceuticals' Research & Development shows a peak YoY skyrocketed of 113.63% (in 2021) over the last 5 years.
  • Recursion Pharmaceuticals' Research & Development (Yearly) stood at $63.3 million in 2020, then soared by 113.63% to $135.3 million in 2021, then rose by 15.10% to $155.7 million in 2022, then skyrocketed by 54.93% to $241.2 million in 2023, then skyrocketed by 30.34% to $314.4 million in 2024.